Clinical trials: Non-small Lung Cancer
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075517
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01259089
- Testing
- erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Carcinoma, Non Small Cell Lung (NSCLC)
Locally Advanced NSCLC Hyperfractionated RT
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC).
- Trial name
- ADAPT (NCT03128008)
- Testing
- Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Renal Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain…
- Conditions
- Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
- Trial name
- NCT01005797
- Testing
- Panobinostat (LBH589), Sorafenib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Lung Cancer (Diagnosis), Fragmentomics
Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
The goal of this observational study is to learn if cfDNA fragmentomics can noninvasively diagnose whether lung nodules are benign or malignant in adults with imaging-detected lung nodules.
- Trial name
- SHC2408 (NCT07399210)
- Testing
- This study did not include intervention between two cohorts
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Baohui Han
Non-Small Cell Lung Cancer
Repositioning Immunotherapy in VetArans With Lung Cancer
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
- Trial name
- RIVAL (NCT06275360)
- Testing
- Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- VA Office of Research and Development
Non-small Cell Lung Cancer
Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC
This observational study is designed to assess the efficacy and safety of pembrolizumab for the treatment of Chinese advanced NSCLC.
- Trial name
- NCT04153097
- Where
- 8 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Lung Cancer
SABR for T1-2a N1 NSCLC
Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series.
- Trial name
- NCT03321760
- Testing
- Stereotactic Ablative Radiation Therapy (SABR)
- Where
- 3 sites in United States
- Sponsor
- Indiana University
Cancer, Tumor, Solid
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or…
- Conditions
- Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05082610
- Testing
- HMBD-002, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hummingbird Bioscience
Non-small Cell Lung Cancer
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in…
- Trial name
- NCT03396497
- Testing
- LYC-55716, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Lycera Corp.
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
Non-small cell lung cancer frequently spreads to the brain, and brain metastases are associated with poor prognosis and limited treatment response.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Neoplasm Metastasis
- Trial name
- SIREC-Poumon (NCT07904013)
- Testing
- Radiomic analysis; Bulk RNA sequencing
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of…
- Trial name
- NCT05603013
- Testing
- Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Non-small Cell Lung Cancer(NSCLC)
Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation
This is an exploratory study in patients with locally advanced or metastatic Non-small cell lung cancer. Patients who are eligible to apply for Extended Access Program of crizotinib must have ALK translocation detected by RT-PCR…
- Trial name
- NCT01637597
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.